Abstract | BACKGROUND & AIMS: METHODS: Patients undergoing liver resection surgery for metastatic disease were randomized to receive rofecoxib 25 mg daily or placebo before surgery (duration, >14 days). The apoptosis index (AI; neocytokeratin 18), proliferation index (PI; Ki-67), and microvessel density (MVD; CD31) were measured in metastases by immunohistochemistry. The effect of rofecoxib on COX-2-positive HCA-7 human CRC cell PGE(2) synthesis, proliferation, and apoptosis in vitro was also investigated. RESULTS: Patients who received rofecoxib (n = 23) and placebo (n = 21) were well matched regarding clinical and metastasis characteristics. The mean (range) duration of rofecoxib therapy was 26 (14-46) days. Rofecoxib-treated metastases had a 29% decrease in MVD (mean, 25.1 [SEM, 2.7] per hpf) compared with placebo-treated tissue (32.5 [SEM, 4.5] per hpf; P = 0.15). There was little difference in AI ( rofecoxib mean, 2.03% [SEM, 0.43%] vs. placebo 1.39% [SEM, 0.39%]) or PI ( rofecoxib 54.7% [SEM, 5.1%] vs. placebo 52.6% [SEM, 5.6%]). Rofecoxib-induced growth arrest and apoptosis of HCA-7 cells occurred only at concentrations (>10 micromol/L), which were significantly higher than the IC(50) for COX-2 inhibition. CONCLUSIONS:
Rofecoxib may negatively regulate angiogenesis in human CRC liver metastases. The absence of a significant, direct effect of rofecoxib on epithelial cells in liver metastases in vivo mirrors the lack of activity on human CRC cells at pharmacologically relevant concentrations in vitro.
|
Authors | Stephen W Fenwick, Giles J Toogood, J Peter A Lodge, Mark A Hull |
Journal | Gastroenterology
(Gastroenterology)
Vol. 125
Issue 3
Pg. 716-29
(Sep 2003)
ISSN: 0016-5085 [Print] United States |
PMID | 12949718
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cyclooxygenase 2 Inhibitors
- Cyclooxygenase Inhibitors
- Isoenzymes
- Lactones
- Membrane Proteins
- Sulfones
- rofecoxib
- Cyclooxygenase 2
- PTGS2 protein, human
- Prostaglandin-Endoperoxide Synthases
- Dinoprostone
|
Topics |
- Aged
- Apoptosis
(drug effects)
- Cell Division
(drug effects)
- Colorectal Neoplasms
(blood supply, drug therapy)
- Cyclooxygenase 2
- Cyclooxygenase 2 Inhibitors
- Cyclooxygenase Inhibitors
(therapeutic use)
- Dinoprostone
(biosynthesis)
- Double-Blind Method
- Female
- Humans
- Isoenzymes
(antagonists & inhibitors)
- Lactones
(therapeutic use)
- Liver Neoplasms
(blood supply, secondary)
- Male
- Membrane Proteins
- Middle Aged
- Prostaglandin-Endoperoxide Synthases
- Sulfones
|